ViferaXS Raises €12M to Advance CLL Phase II Trial
TÜBINGEN, Germany — September 23, 2026 ViferaXS GmbH announced the close of a Series A financing round of up...
Chronic Lymphocytic Leukemia
Advertisement
BeOne Medicines Expands BRUKINSA Access for CLL Patients
SAN CARLOS, Calif. & SEATTLE, Aug. 18, 2026 BeOne Medicines Ltd., together with the BeOne Care Foundation and The...
Dr. Reddy’s Expands Access to Immunotherapy for Rare Head and Neck Cancer
JOHANNESBURG, South Africa / HYDERABAD, India, Aug. 3, 2026 Dr. Reddy’s Laboratories South Africa announced the registration of an...
Dr. Reddy’s Laboratories Secures U.S. FDA Approval for Rituximab Biosimilar
HYDERABAD, India, Aug. 1, 2026 Dr. Reddy’s Laboratories Ltd. announced that the U.S. Food and Drug Administration (FDA) has...
Sanofi’s MenQuadfi Receives EU Approval for Infants From Six Weeks of Age
PARIS, Aug. 4, 2026 Sanofi announced that the European Commission (EC) has approved an expanded indication for MenQuadfi® (Meningococcal...
Advertisements
Nurix Therapeutics Enrolls First Patient in Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg
BRISBANE, Calif., Aug. 4, 2026 Nurix Therapeutics, Inc. announced the enrollment of the first patient in the registrational Phase...
CREATE, Monash Partner to Advance In Vivo CAR-T Platform
CAMBRIDGE, Mass., July 31, 2026 CREATE Medicines has announced a strategic research collaboration and exclusive worldwide licensing agreement with...
Curis Advances TakeAim CLL Trial with First Patients Dosed
LEXINGTON, Mass., July 30, 2026 Curis, Inc. has reached an important clinical milestone by successfully dosing the first five...
Nurix and Roche Complete Strategic Oncology Collaboration
Brisbane, California, USA | July 21, 2026 Nurix Therapeutics announced the official closing of its previously announced global collaboration...
Curis Achieves Early Enrollment in Phase 2 CLL Trial
LEXINGTON, Mass., July 6, 2026 Curis, Inc. announced an important enrollment milestone for its Phase 2 TakeAim CLL clinical...
Advertisement
